Martin SS, Aday AW, Allen NB, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41-e660.
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467.
Engel-Nitz NM, Sander SD, Harley C, et al. Costs and outcomes of noncardioembolic ischemic stroke in a managed care population. Vasc Health Risk Manag. 2010;6:905-913.
Ferrone SR, Boltyenkov AT, Lodato Z, et al. Clinical outcomes and costs of recurrent ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. 2022;31(6):106438.
Flach C, Muruet W, Wolfe CDA, et al. Risk and secondary prevention of stroke recurrence: a population-base cohort study. Stroke. 2020;51(8):2435-2444.
Turan TN, Zaidat OO, Gronseth GS, et al. Stroke prevention in symptomatic large artery intracranial atherosclerosis practice advisory: report of the AAN Guideline Subcommittee. Neurology. 2022;98(12):486-498.
Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke system. Stroke. 2007;38(11):2979-2984.
Arsava EM, Ballabio E, Benner T, et al.; International Stroke Genetics Consortium. The Causative Classification of Stroke system: an international reliability and optimization study. Neurology. 2010;75(14):1277-1284.
Amarenco P, Bogousslavsky J, Caplan LR, et al. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis. 2013;36(1):1-5.
Johnston KC, Connors AF, Wagner DP, et al. Predicting outcome in ischemic stroke: external validation of predictive risk models. Stroke. 2003;34(1):200-202.
Sanders LM, Srikanth VK, Blacker DJ, et al. Performance of the ABCD2 score for stroke risk post TIA: meta-analysis and probability modeling. Neurology. 2012;79(10):971-980.
van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81(7):619-625.
Yeo SH, Toh MPHS, Lee SH, et al. Impact of medication nonadherence on stroke recurrence and mortality in patients after first-ever ischemic stroke: insights from registry data in Singapore. Pharmacoepidemiol Drug Saf. 2020;29(5):538-549.
Smith EE, Saposnik G, Biessels GJ, et al.; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Council on Hypertension. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e44-e71.
Turc G, Lee JY, Brochet E, et al.; CLOSE and DEFENSE-PFO Trial Investigators. Atrial septal aneurysm, shunt size, and recurrent stroke risk in patients with patent foramen ovale. J Am Coll Cardiol. 2020;75(18):2312-2320.
Yaghi S, de Havenon A, Rostanski S, et al. Carotid stenosis and recurrent ischemic stroke: a post-hoc analysis of the POINT trial. Stroke. 2021;52(7):2414-2417.
Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114(3):206-210.
Katsanos AH, Parissis J, Frogoudaki A, et al. Heart failure and the risk of ischemic stroke recurrence: a systematic review and meta-analysis. J Neurol Sci. 2016;362:182-187.
Wang IK, Lien LM, Lee JT, et al.; Taiwan Stroke Registry Investigators. Renal dysfunction increases the risk of recurrent stroke in patients with acute ischemic stroke. Atherosclerosis. 2018;277:15-20.
Zheng S, Yao B. Impact of risk factors for recurrence after the first ischemic stroke in adults: a systematic review and meta-analysis. J Clin Neurosci. 2019;60:24-30.
Epstein KA, Viscoli CM, Spence JD, et al. Smoking cessation and outcome after ischemic stroke or TIA. Neurology. 2017;89(16):1723-1729.
Zhang L, Li X, Wolfe CDA, et al. Diabetes as an independent risk factor for stroke recurrence in ischemic stroke patients: an updated meta-analysis. Neuroepidemiology. 2021;55(6):427-435.
Zhang F, Liu L, Zhang C, et al. Association of metabolic syndrome and its components with risk of stroke recurrence and mortality: a meta-analysis. Neurology. 2021;97(7):e695-e705.
Pennlert J, Asplund K, Glader EL, et al. Socioeconomic status and the risk of stroke recurrence: persisting gaps observed in a nationwide Swedish study 2001 to 2012. Stroke. 2017;48(6):1518-1523.
Brown DL, Shafie-Khorassani F, Kim S, et al. Sleep-disordered breathing is associated with recurrent ischemic stroke. Stroke. 2019;50(3):571-576.
Kolmos M, Christopherson L, Kruuse C. Recurrent ischemic stroke—a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(8):105935.
Kitano T, Hirano T, Okazaki S, et al. Heterogeneity of stroke in patients with systemic lupus erythematosus. Intern Med. 2022;61(20):3045-3052.
Zonneveld TP, Richard E, Vergouwen MDI, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018(7):CD007858.
Willey JZ, Moon YP, Kahn E, et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc. 2014;3(5):e001106.
Kauw F, Takx RAP, de Jong HWAM, et al. Clinical and imaging predictors of recurrent ischemic stroke: a systematic review and meta-analysis. Cerebrovasc Dis. 2018;45(5–6):279-287.
Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38(6):1881-1885.
Wu S, Wu Z, Yu D, et al. Life's Essential 8 and risk of stroke: a prospective community-based study. Stroke. 2023;54(9):2369-2379.
Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43.
Katsanos Ah, Filippatou A, Manios E, et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2017;69(1):171-179.
Hsu CY, Saver JL, Ovbiagele B, et al. Association between magnitude of differential blood pressure reduction and secondary stroke prevention: a meta-analysis and meta-regression. JAMA Neurol. 2023;80(5):506-515.
De Lima LG, Saconato H, Atallah AN, et al. Beta-blockers for preventing stroke recurrence. Cochrane Database Syst Rev. 2014(10):CD007890.
Amarenco P, Bogousslavsky J, Callahan A, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
Yin Y, Zhang L, Marshall I, et al. Statin therapy for preventing recurrent stroke in patients with ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and observational cohort studies. Neuroepidemiology. 2022;56(4):240-249.
Amarenco P, Kim JS, Labreuche J, et al.; Treat Stroke to Target Investigators. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9-19.
Lee M, Cheng CY, Wu YL, et al. Association between intensity of low-density lipoprotein cholesterol reduction with statin-based therapies and secondary stroke prevention: a meta-analysis of randomized clinical trials. JAMA Neurol. 2022;79(4):349-358.
Filion KB, Douros A, Azoulay L, et al. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: a population-based cohort study. Br J Clin Pharmacol. 2019;85(10):2378-2389.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, et al. Antidiabetic drugs and stroke risk. Current evidence. Eur J Intern Med. 2018;48:1-5.
Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017;40(7):821-831.
Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):e007165.
Guo M, Ding J, Li J, et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(8):1977-1982.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2025. Diabetes Care. 2025;48(1 suppl 1):S181-S206.
Larsson SC. Dietary approaches for stroke prevention. Stroke. 2017;48(10):2905-2911.
Dearborn JL, Urrutia VC, Kernan WN. The case for diet: a safe and efficacious strategy for secondary stroke prevention. Front Neurol. 2015;6:1.
Chimowitz MI, Lynn MJ, Derdeyn CP, et al.; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003.
Eapen BC, Tran J, Ballard-Hernandez J, et al. Stroke rehabilitation: synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guidelines. Ann Intern Med. 2025;178(2):249-268.
Parikh NS, Zhang C, Salehi Omran S, et al. Smoking-cessation pharmacotherapy after stroke and transient ischemic attack: a get with the guidelines-stroke analysis. Stroke. 2023;54(3):e63-e65.
Noubiap JJ, Fitzgerald JL, Gallagher C, et al. Rates, predictors, and impact of smoking cessation after stroke or transient ischemic attack: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(10):106012.
Smyth A, O'Donnell M, Rangarajan S, et al.; INTERSTROKE Investigators. Alcohol intake as a risk factor for acute stroke: the INTERSTROKE study. Neurology. 2023;100(2):e142-e153.
Dharmakulaseelan L, Boulos MI. Sleep apnea and stroke: a narrative review. Chest. 2024;166(4):857-866.
Haba-Rubio J, Vujica J, Franc Y, et al. Effect of CPAP treatment of sleep apnea on clinical prognosis after ischemic stroke: an observational study. J Clin Sleep Med. 2019;15(6):839-847.
Kimura S, Toyoda K, Yoshimura S, et al.; SAMURAI, RELAXED, RAF, RAF-NOAC, CROMIS-2, NOACISP LONGTERM, Erlangen Registry and Verona Registry Investigators. Practical “1-2-3-4-Day” rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation: combined hospital-based cohort study. Stroke. 2022;53(5):1540-1549.
Wang Y, Wang Y, Zhao X, et al.; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11-19.
Johnston SC, Easton JD, Farrant M, et al.; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and hgh-risk TIA. N Engl J Med. 2018;379(3):215-225.
Gao Y, Chen W, Pan Y, et al.; INSPIRES Investigators. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023;389(26):2413-2424.
Joglar JA, Chung MK, Armbruster AL, et al.; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
Chi NF, Wen CP, Liu CH, et al.; Taiwan Stroke Registry Investigators. Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data. J Am Heart Assoc. 2018;7(19):e009856.
Paciaroni M, Ince B, Hu B, et al. Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis. Cardiovasc Ther. 2019:1607181.
Wang C, Jia W, Jing J, et al.; CHANCE-2 Investigators. Ticagrelor versus clopidogrel in minor stroke or transient ischemic attack with intracranial artery stenosis: a post hoc analysis of CHANCE-2. J Am Heart Assoc. 2023;12(21):e031611.
Bhatia K, Ladd LM, Carr KH, et al. Contemporary antiplatelet and anticoagulant therapies for secondary stroke prevention: a narrative review of current literature and guidelines. Curr Neurol Neurosci Rep. 2023;23(5):235-262.
de Havenon A, Sheth KN, Madsen TE, et al. Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke. 2021;52(10):e635-e645.
Sacco RL, Diener HC, Yusuf S, et al.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238-1251.
Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330.
Wabnitz AM, Turan TN. Optimal medical management of atherosclerotic intracranial stenosis. Stroke. 2024;55(2):335-343.
Wong KSL, Chen C, Fu J, et al.; CLAIR Study Investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489-497.
Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111(17):2233-2240.
Zaidat OO, Fitzsimmons BF, Woodward BK, et al.; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12):1240-1248.
Gao P, Wang T, Wang D, et al.; CASSISS Trial Investigators. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial. JAMA. 2022;328(6):534-542.
EC/IC Bypass Study Group. Failure of extracranial–intracranial arterial bypass to reduce the risk of ischemic stroke. N Engl J Med. 1985;313(19):1191-1200.
Sun X, Deng Y, Zhang Y, et al.; BASIS Investigators. Balloon angioplasty vs medical management for intracranial artery stenosis: the BASIS randomized clinical trial. JAMA. 2024;332(13):1059-1069.
Chimowitz MI, Lynn MJ, Howlett-Smith H, et al.; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316.
Müller MD, Lyrer PA, Brown MM, et al. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. Stroke. 2021;52(1):e3-e5.
Connolly SJ, Eikelboom J, Joyner C, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
Fischer U, Koga M, Strbian D, et al.; ELAN Investigators. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 2023;388(26):2411-2421.
Camen S, Haeusler KG, Schnabel RB. Cardiac imaging after ischemic stroke or transient ischemic attack. Curr Neurol Neurosci Rep. 2020;20(8):36.
Schwartz BG, Alexander CT, Grayburn PA, et al. Utility of routine transesophageal echocardiography in patients with stroke or transient ischemic attack. Proc Bayl Univ Med Cent. 2018;31(4):401-403.
Benavente OR, Coffey CS, Conwit R, et al.; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507-515.
Xie X, Jing J, Meng X, et al.; CHANCE-2 Investigators. Dual antiplatelet therapies and causes in minor stroke or transient ischemic attack: a prespecified analysis in the CHANCE-2 trial. Stroke. 2023;54(9):2241-2250.
Hart RG, Catanese L, Perera KS, et al. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867-872.
Bahit MC, Sacco RL, Easton JD, et al.; RE-SPECT ESUS Steering Committee and Investigators. Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial. Circulation. 2021;144(22):1738-1746.
Xing LY, Diederichsen SZ, Højberg S, et al. Effects of atrial fibrillation screening according to N-terminal pro-B-type natriuretic peptide: a secondary analysis of the randomized LOOP study. Circulation. 2023;147(24):1788-1797.
Buck BH, Hill MD, Quinn FR, et al. Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the PER DIEM randomized clinical trial. JAMA. 2021;325(21):2160-2168.
Sposato LA, Chaturvedi S, Hsieh CY, et al. Atrial fibrillation detected after stroke and transient ischemic attack: a novel clinical concept challenging current views. Stroke. 2022;53(3):e94-e103.
Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (the LOOP study): a randomised controlled trial. Lancet. 2021;398(10310):1507-1516.
Ghannam M, Al-Qudah AM, Alshaer QN, et al. Anticoagulation vs antiplatelets across subgroups of embolic stroke of undetermined source: a meta-analysis of randomized controlled trials. Neurology. 2024;103(9):e209949.
Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the guideline subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876-885.
Brown KN, ElBebawy B, Shah AH, et al. Catheter management of patent foramen ovale. StatPearls. March 6, 2023. Accessed February 11, 2025. https://www.ncbi.nlm.nih.gov/books/NBK537314/
Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357(18):1821-1828.
Oza R, Rundell K, Garcellano M. Recurrent ischemic stroke: strategies for prevention. Am Fam Physician. 2017;96(7):436-440.
Dickerson LM, Carek PJ, Quattlebaum RG. Prevention of recurrent ischemic stroke. Am Fam Physician. 2007;76(3):382-388.